Dan A-Farber
Total Page:16
File Type:pdf, Size:1020Kb
CANCER INSTITUTE -FARBER -FARBER A AN D Baruj Benacerraf, MD 1920-2011 A LEGacY OF VISIONARY LEADERSHIP 2011 HONOR ROLL OF DONORS ON THE COVER Dana-Farber Cancer Institute lost a visionary leader in 2011 when Institute President CONTENTS Emeritus and Trustee Baruj Benacerraf, MD, A Message from passed away at age 90. the President & CEO of Dana-Farber Cancer Institute . 1 A distinguished immu- nologist and pathologist A Message from whose groundbreaking the Senior Vice President for Development . 2 research earned him a Nobel Laureate in A Message from Medicine, Benacerraf the Trustee Development Committee Co-chairs . 3 also built a tremendous community of supporters. This pub- lication acknowledges our generous donors, who honor Institute Benefactors . 4 Benacerraf’s legacy through their steadfast commitment to New Commitments . 7 advancing the lifesaving mission of Dana-Farber. (Above: Baruj Benacerraf, MD, left, receiving the Nobel Prize in 1980.) Individuals . 9 ABOUT DANA-FARBER CANCER INSTITUTE Dana-Farber Faculty & Staff . 24 & THE JIMMY FUND Dana-Farber Cancer Institute provides expert, compassionate care President’s Circle . 25 to children and adults, and is home to groundbreaking cancer Trustee Giving . 26 discoveries. Since its founding in 1948, the Jimmy Fund has raised hundreds of millions of dollars through thousands of community Corporations, Foundations, Organizations & Trusts . 29 efforts to advance Dana-Farber’s lifesaving mission. Corporate Programs . 37 2011 HONOR ROLL OF DONORS Produced by Dana-Farber Cancer Institute, Division of Development & The Planned Gifts . 41 Jimmy Fund, 10 Brookline Place West, 6th Floor, Brookline, MA 02445-7226 danafarber.org jimmyfund.org For more information or to be removed from our mailing list, please Dana-Farber Society . 42 call 617-632-3019 or 800-52-JIMMY or visit jimmyfund.org/opt-out. Gene Display in the Tomsich Family Gallery . 44 SENIOR VICE PRESIDENT FOR DEVELOPMENT Susan S. Paresky Tribute & Memorial Gifts . 47 ASSISTANT VICE PRESIDENT DEVELOPMENT MARKETING & DONOR RELATIONS Jan Lawlor Named Funds . 50 EDITORS Michela D’Eramo, Lori Dougherty Leadership Committees . 54 LEAD DESIGNER David Ferreira Pan-Massachusetts Challenge . 56 DESIGNER Sharon Veino LIST MANAGER Special Events . 60 Michela D’Eramo LIST COORDINATOR Jimmy Fund Golf . 64 Megan Barrows PHOTOGRAPHY MANAGER Running Programs . 66 Maria Cipicchio ® PRODUCTION COORDINATORS Boston Marathon Jimmy Fund Walk . 68 Maria Cipicchio, Katie Connors CONTRIBUTORS Palm Beach . 70 Alan Caplan, Amy Chambers, Brenda Chroniak, Jane Cormuss, Rebecca DuFault, Catherine Dunphy, Mark ElBach, Brigham Fay, Sahil Gandhi, Dee Groom, Friends of Dana-Farber Cancer Institute . 72 Kelsie Guerriero, Katherine Harper, Kathleen Hughes, Corinna McFarland, Lisa Oteri, Jacqueline Shydlowski, Jennifer Skala, Michael Taksa, Christopher Teehan, Cody Waters, Jay Welz, Monica Zurlinden Platelet Donors . 74 PHOTOGRAPHERS Bryan Barth, Mark Bogacz, brightroom.com, Lucien Capehart, Lisa Cohen, Volunteers . 76 Ryan Delaney, John Deputy, Driscoll Photography, Essex Television, Richard Gastwirt, Rebecca Gavin, David Giagrando, Steve Gilbert, David Gilmore, Kaitlin Hyde, Drew Hyman, Channing Johnson, Yousuf Karsh, Eric Kaye, Traci Klier, Justin Knight, Lindsey Larsen, Kelly Lauriat, Aviran Levy, Jane Maier, Arturo Martinez, Steve McLaughlin, Al Micciche, Craig Nichols, Sam Ogden, Jennifer Nourse Rodman, Andrea Rowlings, Jocelyn Vara, Aaron Washington © 2011 Dana-Farber Cancer Institute 2011 HONOR ROLL OF DONORS 1 WELCOME A MESSAGE FROM THE PRESIDENT & CEO OF DANA-FARBER CANCER INSTITUTE Dear Friends, Baruj Benacerraf, MD, Dana-Farber President Emeritus and Trustee who passed away in August 2011, leaves us a great legacy of leadership. His ability to attract top scientific talent, cultivate a dedicated community of supporters, and expand the physical footprint of Dana-Farber set the Institute on a path of excellence. Equally important, his discoveries about the immune system and the basic processes of diseases changed the course of medical research. This legacy of visionary science has resulted today in a new landscape for cancer medicine, one where we are increasingly able to provide the best possible treatment for each individual patient. All of us at the Insti- tute appreciate your support of Dana-Farber at this critical juncture. We started 2011 by opening the doors of our new Yawkey Center for Your passion, leadership, Cancer Care. This building sets a new standard for cancer care and and generosity keep us embodies what makes Dana-Farber special: an unwavering commitment to innovation and discovery while providing an exceptional level of com- at the forefront. passionate care for our patients. In March, the FDA approved the use of a new drug, ipilimumab, which was shown effective for patients with advanced melanoma in a national clinical study led by Dana-Farber’s F. Stephen Hodi, MD. The success of this new class of drugs holds out great promise to make an impact for patients everywhere by moving us closer toward the successful delivery of personalized medicine. August brought the launch of Profile, our comprehensive cancer research study, which aims to routinely and reliably detect cancer-causing genetic mutations in tumor samples, so that the most effective treatments can be given to patients based on their genetic profile. This is the critical first step in delivering personalized medicine on a very large scale, and we remain grateful for your partnership in these efforts. These are just a few of the ways that Dana-Farber pushes forward, unrelenting in our commitment to conquering cancer and determined to continue making the advances that represent the promise of a brighter future for our patients and their families. Your passion, leadership, and generosity help the Institute remain a leader in groundbreaking research and innovative care. Simply put, we could not do it without you and for that, we are profoundly grateful. Thank you for the role that you play in keeping us at the forefront. Sincerely, Edward J. Benz Jr., MD 2 2011 HONOR ROLL OF DONORS WELCOME A MESSAGE FROM THE SENIOR VICE PRESIDENT FOR DEVELOPMENT Dear Friends, When you are faced with a cancer diagnosis, there is a sense of comfort that comes from knowing you are not alone. Whether you join an online forum to connect with others facing the same dis- ease, rely on a core group of loved ones to come with you to your appointments, or share your journey with a counselor or trusted friend, as a patient, you can find strength in leaning on others. As President of Dana-Farber from 1980 to 1992, Baruj Benacerraf, MD, possessed a passion for patients and families that inspired a strong donor base whose generosity says to those battling this insidious disease: “You are not alone.” Although Dr. Benacerraf passed away in 2011, his work as a visionary in the field of immunology, coupled with his extraordinary leadership, built a robust community of supporters who continue to ensure the Because of you, our patients Institute’s financial future today. know they are not alone As members of this growing community, your message to patients and their families was heard loud and clear in 2011. Your support in the fight against cancer. poured in with an impressive 347,000 gifts, including 112,000 new donors and 16 gifts of $1 million or more. In total, a stunning $168 million was raised to advance the Institute’s mission and sustain the work of our pioneering physician-scientists, ultimately providing strength, encouragement, and hope to our patients and their families. Please know that the Dana-Farber team—doctors, scientists, nurses, administrators, faculty, and staff—shares my heartfelt pride in having you as part of our community. Thank you for helping us make measureable progress in the fight against cancer. INDIVIDUALS 30.9% PMC 19.7% Sincerely, EVENTS 16.4% BEQUESTS 2.3% Susan S. Paresky CORPORATIONS 6.2% FOUNDATIONS 24.5% Total raised by the Jimmy Fund ($63 million of the $168 million raised) A NOTE TO OUR SUPPORTERS We have carefully reviewed all gifts made to Dana-Farber Cancer Institute, the Jimmy Fund, the Pan-Massachusetts Challenge (PMC), and the Friends of Dana-Farber Cancer Institute to ensure that each gift is properly recognized. A description of the criteria for inclusion precedes each section of the pages that follow. The 2011 Honor Roll of Donors includes gifts made between October 1, 2010, and September 30, 2011. Occasionally, despite our best efforts, errors occur. If we have made mistakes, we sincerely apologize. Please alert us to such errors by contacting the Division of Development and the Jimmy Fund at 617-632-3019 or 800-52-JIMMY (54669) or 10 Brookline Place West, 6th Floor, Brookline, MA 02445-7226. Please note that we make every effort to follow donors’ preferences when compiling the Honor Roll of Donors. If you would prefer to have your name listed differently in the future, please let us know. 2011 HONOR ROLL OF DONORS 3 WELCOME A MESSAGE FROM THE TRUSTEE DEVELOPMENT COMMITTEE CO-CHAIRS Dear Friends, Each year we are struck by the power of Dana-Farber’s devoted community of donors. On behalf of the Board of Trustees, we thank you for demonstrat- ing again and again your commitment to our lifesaving mission in such a wide variety of ways. Your efforts—whether making an annual gift, running 26.2 miles or biking 190, playing a round of golf, supporting an investiga- tor’s research, or including Dana-Farber in your estate plans—are all critical to the Institute’s continued progress against cancer and its related diseases. Fundraising highlights of 2011 include: • The incredible support of our loyal friends in Palm Beach, Fla., who marked their 20th season by raising an outstanding $2.3 million—a three-year high; • A bold commitment to improving healthcare from Institute Trustee Robert You are part of a powerful Kraft, his late wife, Myra, and their children, Jonathan, Daniel, Josh, and David, which directs $5 million to support Dana-Farber’s community community that, together, cancer programs and women’s cancer research; is making a difference.